Gluz O, Kates R, Kuemmel S, Nitz U, et al. A tale of two trials: TAILORx and PlanB. Letter to the Editor regarding "Impact of anthracyclines in genomic high-risk, node-negative, HR-positive/ HER2-negative breast cancer" by Chen et al. Ann Oncol 2025 Dec 20:S0923-7534(25)06333-1. doi: 10.1016/j.annonc.2025.
PMID: 41429308